/PRNewswire/ Results of a study published today in Frontiers in Pediatrics have revealed critical missing information linking potentially pathogenic gut.
/PRNewswire/ Results of a study published today in Frontiers in Pediatrics have revealed critical missing information linking potentially pathogenic gut.
EVOLVE BIOSYSTEMS: STUDY DEMONSTRATES NOVEL BIOCHEMICAL MECHANISM OF NECROTIZING ENTEROCOLITIS (NEC), A LEADING CAUSE OF PREMATURE MORBIDITY AND MORTALITY streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Investors Continue to Support Breakthrough Research on Infant Gut Health
Evolve s final round of funding will help further the brand s goal of resolving Newborn Gut Deficiency in the U.S.
News provided by
Share this article
DAVIS, Calif., May 25, 2021 /PRNewswire/
Evolve BioSystems, Inc., a privately-held leading microbiome company, announced today the second and final close of its Series D round of funding exceeding $65 million, led by investors Cargill and Manna Tree. Oversubscribed from original expectations, this second closing of the Series D will accelerate the company s mission to research and address Newborn Gut Deficiency (NGD), a dramatic shortage of key good bacteria in the infant gut microbiome, and thus improve the health of infants worldwide.